EA010886B1 - Фармацевтическая композиция, способ ее получения и ее применение для лечения респираторных заболеваний, фармацевтический продукт и его применение, набор - Google Patents

Фармацевтическая композиция, способ ее получения и ее применение для лечения респираторных заболеваний, фармацевтический продукт и его применение, набор Download PDF

Info

Publication number
EA010886B1
EA010886B1 EA200601592A EA200601592A EA010886B1 EA 010886 B1 EA010886 B1 EA 010886B1 EA 200601592 A EA200601592 A EA 200601592A EA 200601592 A EA200601592 A EA 200601592A EA 010886 B1 EA010886 B1 EA 010886B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
active ingredient
solvate
group
oxide
Prior art date
Application number
EA200601592A
Other languages
English (en)
Russian (ru)
Other versions
EA200601592A1 (ru
Inventor
Рольф Бойме
Даниела Бундшух
Кристиан Ваймар
Штефан-Лутц Воллин
Original Assignee
Никомед Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Никомед Гмбх filed Critical Никомед Гмбх
Publication of EA200601592A1 publication Critical patent/EA200601592A1/ru
Publication of EA010886B1 publication Critical patent/EA010886B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EA200601592A 2002-03-06 2003-02-25 Фармацевтическая композиция, способ ее получения и ее применение для лечения респираторных заболеваний, фармацевтический продукт и его применение, набор EA010886B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06

Publications (2)

Publication Number Publication Date
EA200601592A1 EA200601592A1 (ru) 2006-12-29
EA010886B1 true EA010886B1 (ru) 2008-12-30

Family

ID=27771841

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200601592A EA010886B1 (ru) 2002-03-06 2003-02-25 Фармацевтическая композиция, способ ее получения и ее применение для лечения респираторных заболеваний, фармацевтический продукт и его применение, набор
EA200401137A EA007903B1 (ru) 2002-03-06 2003-02-25 Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200401137A EA007903B1 (ru) 2002-03-06 2003-02-25 Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора

Country Status (31)

Country Link
US (1) US20050112069A1 (enExample)
EP (2) EP1849468B1 (enExample)
JP (1) JP5150034B2 (enExample)
KR (1) KR20040095255A (enExample)
CN (1) CN101257904A (enExample)
AR (1) AR038858A1 (enExample)
AT (1) ATE369134T1 (enExample)
AU (1) AU2003212268B2 (enExample)
BR (1) BR0308220A (enExample)
CA (1) CA2478612C (enExample)
CO (1) CO5611148A2 (enExample)
CY (2) CY1106927T1 (enExample)
DE (1) DE60315426T2 (enExample)
DK (2) DK1482938T3 (enExample)
EA (2) EA010886B1 (enExample)
ES (2) ES2400670T3 (enExample)
HR (1) HRP20040909B1 (enExample)
IL (1) IL163336A (enExample)
IS (2) IS2536B (enExample)
MX (1) MXPA04008460A (enExample)
NO (1) NO335254B1 (enExample)
NZ (1) NZ535611A (enExample)
PL (1) PL211574B1 (enExample)
PT (2) PT1482938E (enExample)
RS (1) RS51018B (enExample)
SG (1) SG160197A1 (enExample)
SI (2) SI1849468T1 (enExample)
TW (1) TWI347845B (enExample)
UA (1) UA80117C2 (enExample)
WO (1) WO2003074055A1 (enExample)
ZA (1) ZA200407104B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2671491C2 (ru) * 2013-06-28 2018-11-01 Ханми Фарм. Ко., Лтд. Комплексная гранулированная композиция, обладающая улучшенной стабильностью, включающая левоцетиризин и монтелукаст

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2008074803A2 (en) * 2006-12-20 2008-06-26 Glaxo Group Limited 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CA2682730A1 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnf.alpha. plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
WO2009067597A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf 4- (or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
RS55624B1 (sr) 2011-02-07 2017-06-30 Scipharm Sàrl Nova kompozicija za lečenje cistične fibroze
CN106604747A (zh) * 2014-08-26 2017-04-26 基础应用医学研究基金会 用于治疗和预防伴随认知缺陷或缺损的神经障碍以及神经变性疾病的产品
NZ731344A (en) 2014-10-09 2018-08-31 Guangdong Raynovent Biotech Co Ltd Hydroxyl purine compounds and applications thereof
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962464A (en) * 1997-02-11 1999-10-05 Sepracor Inc. Methods and compositions for treating allergic asthma using descarboethoxyloratadine
EP1005865A1 (en) * 1998-11-10 2000-06-07 Panacea Biotec Limited A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine
WO2001030777A1 (en) * 1999-10-25 2001-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
WO2003000289A1 (en) * 2001-06-20 2003-01-03 Glaxo Group Limited Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962464A (en) * 1997-02-11 1999-10-05 Sepracor Inc. Methods and compositions for treating allergic asthma using descarboethoxyloratadine
EP1005865A1 (en) * 1998-11-10 2000-06-07 Panacea Biotec Limited A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine
WO2001030777A1 (en) * 1999-10-25 2001-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
WO2003000289A1 (en) * 2001-06-20 2003-01-03 Glaxo Group Limited Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDRI L. ET AL.: "Combined treatment of allergic rhinitis with terfenadine and nimesulide, a non-steroidal antiinflammatory drug", ALLERGIE ET IMMUNOLOGIE, NOUVELLES EDITIONS MEDICALES FRANCAISES, PARIS, FR, vol. 24, no. 8, October 1992 (1992-10), pages 313-314, 317-319, XP002102388, ISSN: 0397-9148, abstract, page 314, column 1, last paragraph *
HATZELMANN A. ET AL.: "ANTI-INFLAMMATORY AND IMMUNOMODULATORY POTENTIAL OF THE NOVEL PDE4 INHIBITOR ROFLUMILAST IN VITRO", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN, SOCIETY FOR PHARMACOLOGY AND, US, vol. 297, no. 1, 2001, pages 267-279, XP001024814, ISSN: 0022-3565, page 277, paragraph 2, page 277, paragraph 4, page 278, paragraph 2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2671491C2 (ru) * 2013-06-28 2018-11-01 Ханми Фарм. Ко., Лтд. Комплексная гранулированная композиция, обладающая улучшенной стабильностью, включающая левоцетиризин и монтелукаст

Also Published As

Publication number Publication date
SI1482938T1 (sl) 2007-12-31
RS78004A (sr) 2006-12-15
DK1482938T3 (da) 2007-12-03
AU2003212268A1 (en) 2003-09-16
EP1482938B1 (en) 2007-08-08
EA200401137A1 (ru) 2005-04-28
ATE369134T1 (de) 2007-08-15
EP1849468B1 (en) 2012-12-05
PT1849468E (pt) 2013-02-27
EA007903B1 (ru) 2007-02-27
HK1071308A1 (en) 2005-07-15
EP1482938A1 (en) 2004-12-08
CA2478612A1 (en) 2003-09-12
IS2536B (is) 2009-08-15
WO2003074055A1 (en) 2003-09-12
SI1849468T1 (sl) 2013-03-29
ES2400670T3 (es) 2013-04-11
DE60315426T2 (de) 2008-07-03
JP5150034B2 (ja) 2013-02-20
AU2003212268B2 (en) 2008-09-11
CO5611148A2 (es) 2006-02-28
ES2291618T3 (es) 2008-03-01
UA80117C2 (uk) 2007-08-27
AR038858A1 (es) 2005-01-26
PT1482938E (pt) 2007-11-15
CY1113894T1 (el) 2016-07-27
CN101257904A (zh) 2008-09-03
EA200601592A1 (ru) 2006-12-29
EP1849468A2 (en) 2007-10-31
JP2005524666A (ja) 2005-08-18
IS8760A (is) 2008-09-04
HRP20040909A2 (en) 2005-08-31
US20050112069A1 (en) 2005-05-26
SG160197A1 (en) 2010-04-29
HRP20040909B1 (en) 2012-11-30
NZ535611A (en) 2006-03-31
NO335254B1 (no) 2014-10-27
DE60315426D1 (de) 2007-09-20
DK1849468T3 (da) 2013-02-04
CA2478612C (en) 2013-12-10
PL371056A1 (en) 2005-06-13
KR20040095255A (ko) 2004-11-12
BR0308220A (pt) 2005-01-04
MXPA04008460A (es) 2004-12-06
RS51018B (sr) 2010-10-31
IS7438A (is) 2004-09-03
CY1106927T1 (el) 2012-09-26
IL163336A (en) 2009-02-11
NO20044230L (no) 2004-12-06
TW200306855A (en) 2003-12-01
TWI347845B (en) 2011-09-01
EP1849468A3 (en) 2007-11-07
PL211574B1 (pl) 2012-05-31
ZA200407104B (en) 2006-12-27

Similar Documents

Publication Publication Date Title
EP1671651B1 (en) Synergistic combination of pumafentrine and salmeterol
AU775588B2 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
JP2005539042A (ja) 呼吸器疾患、アレルギー性疾患、喘息及びｃｏｐｄを処置するためのグルココルチコイド及びｐｄｅ−４−阻害剤の新規組合せ
EP1849468B1 (en) Pharmaceutical composition comprising roflumilast and levocetirizine
KR101071798B1 (ko) 로플루미래스트와 포르모테롤을 포함하는 신규한상승작용성 조합물
KR20210131996A (ko) 과다복용 및 보상-기반 장애의 치료를 위한 조성물, 장치 및 방법
EP0640338A1 (en) Sodium cromoglycate for the treatment of upper respiratory tract infections
EP1567140B1 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
HK1071308B (en) Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
JPH04270221A (ja) 急性腎不全の治療のための薬剤
JP2001089375A (ja) 感冒用組成物
HK1081862B (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
HK1081861B (en) New synergistic combination comprising roflumilast and formoterol
JPWO2005056009A1 (ja) 肺疾患治療剤

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU